Oscar Health, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
OSCR$33.47+4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| (in thousands) | 2025 | 2024 | 2025 | 2024 |
| Common stock, Class A shares | ||||
| Balance, beginning of period | 217,983 | 200,497 | 214,974 | 193,875 |
| Issuance of common stock from equity incentive plans | 5,034 | 5,656 | 8,101 | 12,278 |
| Shares withheld for net settlement of share-based awards | (105) | — | (163) | — |
| Balance, end of period | 222,912 | 206,153 | 222,912 | 206,153 |
| Common stock, Class B shares | ||||
| Balance, beginning of period | 35,514 | 35,514 | 35,514 | 35,514 |
| Issuance of common stock from equity incentive plans | — | — | — | — |
| Balance, end of period | 35,514 | 35,514 | 35,514 | 35,514 |
| Common stock, Class A | ||||
| Balance, beginning of period | $2 | $2 | $2 | $2 |
| Balance, end of period | 2 | 2 | 2 | 2 |
| Common Stock, Class B | ||||
| Balance, beginning of period | — | — | — | — |
| Balance, end of period | — | — | — | — |
| Treasury stock | ||||
| Balance, beginning of period | (2,923) | (2,923) | (2,923) | (2,923) |
| Balance, end of period | (2,923) | (2,923) | (2,923) | (2,923) |
| Additional paid-in capital | ||||
| Balance, beginning of period | 3,902,373 | 3,736,885 | 3,869,617 | 3,682,294 |
| Stock-based compensation expense | 27,474 | 31,298 | 55,357 | 58,580 |
| Issuance of common stock from equity incentive plans | 23,568 | 18,702 | 29,295 | 46,011 |
| Net settlement for taxes related to share-based awards | (1,435) | — | (2,289) | — |
| Balance, end of period | 3,951,980 | 3,786,885 | 3,951,980 | 3,786,885 |
| Accumulated Deficit | ||||
| Balance, beginning of period | (2,576,012) | (2,699,347) | (2,851,283) | (2,876,715) |
| Net income (loss) | (228,361) | 56,207 | 46,910 | 233,575 |
| Balance, end of period | (2,804,373) | (2,643,140) | (2,804,373) | (2,643,140) |
| Accumulated other comprehensive income (loss) | ||||
| Balance, beginning of period | 9,601 | (2,594) | (1,827) | 1,309 |
| Unrealized gains (loss) on investments, net | 4,119 | (31) | 15,547 | (3,934) |
| Balance, end of period | 13,720 | (2,625) | 13,720 | (2,625) |
| Noncontrolling interests | ||||
| Balance, beginning of period | 3,074 | 2,264 | 2,839 | 2,150 |
| Net income (loss) attributable to noncontrolling interests | (130) | 105 | 105 | 219 |
| Balance, end of period | 2,944 | 2,369 | 2,944 | 2,369 |
| Total stockholders' equity | $1,161,350 | $1,140,568 | $1,161,350 | $1,140,568 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.